Cargando…

Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms’ R&D Investment in China? An Event Study Approach

Innovation is the key to the development of the pharmaceutical industry. The pilot program of China’s “4 + 7” volume-based procurement policy (“4 + 7” procurement policy) brings the drug price back to a reasonable level through trading procurement quantities for lower drug prices. The policy manages...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yuanyuan, Chen, Shouming, Qiu, Fangjun, Chen, Peien, Chen, Shaoxiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623542/ https://www.ncbi.nlm.nih.gov/pubmed/34831803 http://dx.doi.org/10.3390/ijerph182212037

Ejemplares similares

The Impact of Two-Invoice System on Pharmaceutical Manufacturers’ Selling Expenses in China: A Difference-in-Differences Approach
por: Ran, Yi, et al.
Publicado: (2022)

The impact of economic policy uncertainty on firms’ investment in innovation: Evidence from Chinese listed firms
por: Kun, Wen, et al.
Publicado: (2022)

Improving access to medicines and beyond: the national volume-based procurement policy in China
por: Zhu, Zheng, et al.
Publicado: (2023)

Pharmaceutical procurement among public sector procurers in CARICOM
por: Preston, Charles, et al.
Publicado: (2021)

Public funding and private investment for R&D: a survey in China’s pharmaceutical industry
por: Qiu, Lan, et al.
Publicado: (2014)

R&D Investments, Debt Capital, and Ownership Concentration: A Three-Way Interaction and Lag Effects on Firm Performance in China's Pharmaceutical Industry
por: Su, Chih-Yi, et al.
Publicado: (2021)

Collective pharmaceutical procurement in China may have unintended consequences in supply and pricing
por: Jiang, Shan, et al.
Publicado: (2020)

Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China
por: Yuan, Jing, et al.
Publicado: (2021)

Behavior Towards R&D Investment of Family Firms CEOs: The Role of Psychological Attribute
por: Zulfiqar, Muhammad, et al.
Publicado: (2021)

Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series
por: Long, Hongfei, et al.
Publicado: (2022)

Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China
por: Zhao, Xinyu, et al.
Publicado: (2022)

To Invest or Not to Invest, That Is the Question: Analysis of Firm Behavior under Anticipated Shocks
por: Kovac, Dejan, et al.
Publicado: (2016)

Impact of China’s National Centralized Drug Procurement Policy on pharmaceutical enterprises’ financial performance: a quasi-natural experimental study
por: Sun, Zhixuan, et al.
Publicado: (2023)

The impacts of economic policy uncertainty on firm cash holding in China
por: Chen, Xin, et al.
Publicado: (2023)

Does China’s centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model
por: Gu, Yang, et al.
Publicado: (2023)

CERN Procurement Strategy and Policy
Publicado: (2011)

The Impact of Firm’s Unethical Behavior in Investment Decisions Among Young Investors in China
por: Tang, Xuelian, et al.
Publicado: (2022)

Survey data on digitalization of building procurement process by architectural firms in Abuja, Nigeria
por: Ibem, Eziyi O., et al.
Publicado: (2018)

COVID-19 impact on firm investment—Evidence from Chinese publicly listed firms
por: Jiang, Jie, et al.
Publicado: (2021)

Firm information disclosure environment and R&D investment: Evidence from Internet penetration
por: Wang, Yukun, et al.
Publicado: (2021)

Healthy Food Procurement Policies and Their Impact
por: Niebylski, Mark L., et al.
Publicado: (2014)

Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus
por: Yuan, Jing, et al.
Publicado: (2022)

Investment expectations by vulnerable European firms in times of COVID
por: Coad, Alex, et al.
Publicado: (2022)

Behavioural Psychology of Unique Family Firms Toward R&D Investment in the Digital Era: The Role of Ownership Discrepancy
por: Zulfiqar, Muhammad, et al.
Publicado: (2022)

Can capital markets identify heterogeneous environmental investment strategies of firms? Evidence from China
por: Cheng, Hongwei, et al.
Publicado: (2023)

The Impact of the Consistency Evaluation Policy of Generic Drugs on R&D Investment Intensity of Pharmaceutical Companies—An Empirical Study Based on the Difference-in-Differences Model
por: Wei, Yanyi, et al.
Publicado: (2022)

Family Exit and Firms' Investment Efficiency Based on Dynamic Changes: Evidence from Chinese Family Firms
por: Wang, Tengyan, et al.
Publicado: (2022)

PHARMACEUTICAL PRICING IN EMERGING MARKETS: EFFECTS OF INCOME, COMPETITION, AND PROCUREMENT
por: Danzon, Patricia M, et al.
Publicado: (2015)

The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis
por: Wang, Xiao, et al.
Publicado: (2023)

The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
por: Chen, Lei, et al.
Publicado: (2020)

The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
por: Yang, Ying, et al.
Publicado: (2021)

Governance quality indicators for organ procurement policies
por: Rodríguez-Arias, David, et al.
Publicado: (2021)

Shareholder personal risk and firm risk: An empirical analysis of share pledges and firm debt policies
por: Xia, Jiahui, et al.
Publicado: (2022)

Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts
por: Gleeson, Deborah, et al.
Publicado: (2019)

The Regulatory Effect of Firm Size on Digital Transformation: An Empirical Study of Pharmaceutical Companies in China
por: Luo, Xiaowen, et al.
Publicado: (2022)

A double-edged sword: The effects of R&D intensity and capitalization on institutional investment in entrepreneurial firms
por: Feng, Yuan, et al.
Publicado: (2022)

Behavioural Phenomena of Family Firm Control Diversity and R&D Investment with Moderating Role CEO Compensation
por: Ghafoor, Sadeen, et al.
Publicado: (2023)

Reevaluation of adverse drug reactions of psychiatric drugs under the chinese drug volume-based procurement policy
por: Du, Zhiqiang, et al.
Publicado: (2022)

A procurement‐based classification of pharmaceutical supplies for diabetes disease management
por: Abdulsalam, Yousef, et al.
Publicado: (2022)

Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
por: Shaikh, Mujaheed, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o7gptlj88qkvk59ubvs3pk9iim